- Contiguous x-chromosome deletion syndrome encompassing the BTK, TIMM8A, TAF7L, and DRP2 genes2007 | Second Faculty of Medicine
- Research Report University Hospital for clinical evaluation of PCI-32765MCL3002Publication without faculty affiliation
- Impaired Toll-like receptor 8-mediated IL-6 and TNF-alpha production in antigen-presenting cells from patients with X-linked agammaglobulinemia +12007 | Second Faculty of Medicine
- Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202)2021 | Faculty of Medicine in Hradec Králové
- Targeting phosphatidylinositol 3 kinase-beta and -delta for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma2020 | First Faculty of Medicine
- Detailed Functional and Proteomic Characterization of Fludarabine Resistance in Mantle Cell Lymphoma Cells2015 | First Faculty of Medicine
- Bruton's Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib Counteract Anthracycline Resistance in Cancer Cells Expressing AKR1C32020 | Faculty of Pharmacy in Hradec Králové
- Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B Cells2020 | Second Faculty of Medicine, First Faculty of Medicine
- A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study2020 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Managing BTK inhibitor treatment-related adverse events in patients with chronic lymphocytic leukaemia - cardiovascular complications and bleeding2023 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial2020 | First Faculty of Medicine
- Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial2023 | Faculty of Medicine in Hradec Králové
- Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia2023 | Faculty of Medicine in Hradec Králové